-
1.发明申请
公开(公告)号：WO2023083850A1
公开(公告)日：2023-05-19
申请号：PCT/EP2022/081234
申请日：2022-11-09
申请人： UNIGROUP APS
发明人： LICHT, Flemming
摘要： An ethyl lactate serves as an active agent for use as a medicament for inhalation or breathing. The medicament is useful in the treatment of pulmonary diseases, the prophylactic treatment of pulmonary diseases, and/or the symptomatic treatment of pulmonary diseases.
-
公开(公告)号：WO2023041776A1
公开(公告)日：2023-03-23
申请号：PCT/EP2022/075941
申请日：2022-09-19
申请人： N.V. NUTRICIA
IPC分类号： A23L33/12 , A23L33/13 , A23L33/19 , A61K31/14 , A61K31/202 , A61K31/22 , A61K31/7072 , A61P25/00 , A61P25/28
摘要： The invention pertains to a solid composition suitable for treating adult animals that suffer from brain-related disorders, brain-related decline or brain-related diseases, preferably suitable for treating adult animals that suffer from brain-related disorders, the composition containing (i) a uridine source, wherein the amount of the sum of all uridine sources, calculated on the basis of the weight of the molar equivalent of uridine monophosphate (UMP), is 0.3-15 g per 100 g dry weight of the composition, (ii) a polyunsaturated fatty acid, preferably an omega-3 polyunsaturated fatty acid, (iii) choline bitartrate, (iv) a buffering salt component, and (v) a milk protein source, wherein the milk protein source is a milk powder, and the buffering salt component containing at least one food approved salt, with a buffering capacity between pH 5 – 8, the buffering salt component preferably containing a mixture of food-approved salts, or a food-approved salt and its conjugated acid or base.
-
公开(公告)号：WO2023281034A1
公开(公告)日：2023-01-12
申请号：PCT/EP2022/069015
申请日：2022-07-07
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITÉ D'ANGERS , CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS
摘要： The present invention relates to the treatment of acidosis related diseases. In this study, the inventors have investigated how human monocytes adapt, survive and differentiate into macrophages under lactic acidosis. Experiments were conducted under atmospheric oxygen and in the presence of glucose, to rule out an effect of oxygen or glucose deprivation. Prolonged exposure to LA affected monocyte/macrophage metabolism. Extracellular acidosis induced mitochondrial membrane depolarization and significantly decreased nutrient consumption, resulting in a dependence of the macrophages on a transient phase of autophagy for survival. In fasting conditions, hepatocytes produce the ketone bodies acetoacetate (AcAc) and β-hydroxybutyrate (β-OHB) that constitute alternative fuel for extrahepatic cells. The inventors found here that AcAc protected the mitochondria from acidosis-induced depolarization and mitophagy, allowing the cells to continue to metabolize nutrients, thereby avoiding the need for self-catabolism to survive. Acetoacetate therefore appears to be a crucial alternative fuel metabolite of potential therapeutic interest to increase tissue tolerance to lactic acidosis. Thus, the invention relates to the acetoacetate (AcAc) for use in the treatment of acidosis related diseases.
-
公开(公告)号：WO2022223778A1
公开(公告)日：2022-10-27
申请号：PCT/EP2022/060682
申请日：2022-04-22
发明人： PRESSLER, Frank , CHEN, Fangfang , WINTERHOFF, Moritz , BÜSSOW, Konrad , BLANKENFELD, Wulf , HIRSCH, Anna , ELGAHER, Walid A. M.
摘要： The invention relates to citraconic acid (CA) or derivative thereof for use as medicament. The invention further relates to citraconic acid or derivative thereof for use in the treatment of a medical condition associated with inflammation. In another aspect, the invention relates to a citraconic acid derivative according to formulae l-XIII. In another aspect, the invention relates to a pharmaceutical composition comprising citraconic acid or derivative thereof with one or more pharmaceutical excipients for use in the treatment of a medical condition, such as those associated with inflammation and/or a non-inflammation associated medical condition.
-
公开(公告)号：WO2022140458A1
公开(公告)日：2022-06-30
申请号：PCT/US2021/064711
申请日：2021-12-21
发明人： GONG, Bing , ZHONG, Yulong
IPC分类号： A61K31/22 , C07C69/003 , C07C69/18
摘要： Provided are compounds that are suitable for cryopreservation of cells. The compounds are non-toxic, water soluble, and free of any organic solvents. The compounds have the following structure: Formula (I), where n is 1, 2, 3, or 4 and each R is independently H or Formula (II), where each R' is independently chosen from aliphatic groups, aryl groups, and amino acid groups and at least one R is not H and the asterisked carbon has R or S stereochemistry or a racemate thereof. Also provided are compositions and methods of using the compounds to cryopreserve cell populations.
-
公开(公告)号：WO2022128054A1
公开(公告)日：2022-06-23
申请号：PCT/EP2020/085964
申请日：2020-12-14
申请人： SYMRISE AG
IPC分类号： A61K31/015 , A61K31/045 , A61K31/11 , A61K31/121 , A61K31/122 , A61K31/22 , A61K31/275 , A61K31/351 , A61K31/357 , A61K31/36 , A61K31/365 , A61K36/15 , A61K36/268 , A61K36/28 , A61K36/54 , A61K36/61 , A61K36/67 , A61K45/06 , A61P29/00 , A61K8/31
摘要： Suggested are agonists of olfactory receptors, particularly OR2AT4, showing (i) a molecular weight ranging from about 50 to about 300 Dalton and (ii) an evaporation rate versus butyl acetate of about 3 to about 15 for use as a medicament for fighting inflammatory conditions of human skin associated with increased expression of interleukin-8.
-
公开(公告)号：WO2022113693A1
公开(公告)日：2022-06-02
申请号：PCT/JP2021/040719
申请日：2021-11-05
IPC分类号： A61K31/22 , A23L33/115 , A23L33/125 , A23L33/17 , A61K31/7004 , A61K31/7016 , A61K31/702 , A61K31/715 , A61K36/889 , A61K38/16 , A61P21/00 , A61P43/00
摘要： 筋ジストロフィー治療剤は、中鎖脂肪酸トリグリセリドを有効成分とする。
-
公开(公告)号：WO2022051029A2
公开(公告)日：2022-03-10
申请号：PCT/US2021/041197
申请日：2021-07-10
IPC分类号： A61K31/506 , A61K31/5377 , A61K45/06 , A61K31/165 , A61K31/22 , A61K31/397 , A61K31/609 , A61K33/24
摘要： In one aspect, use of compounds as active agents to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. Momelotinib and Fedratinib exhibit excellent protection against antibiotic-induced hearing loss in zebrafish and mice when administered prophylactically. In one aspect, Momelotinib or Fedratinib can be used as a therapy for the treatment and/or prevention of hearing loss. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
-
公开(公告)号：WO2022011325A8
公开(公告)日：2022-01-13
申请号：PCT/US2021/041199
申请日：2021-07-10
IPC分类号： A61K31/167 , A61K31/4035 , A61K45/06 , A61K31/165 , A61K31/22 , A61K31/397 , A61K31/609 , A61K33/24
摘要： Acquired hearing loss due to chemotherapy or noise exposure is a major health problem, and Cisplatin chemotherapy often causes permanent hearing loss in cancer patients. However, there are no FDA-approved drugs for the treatment or prevention of Cisplatin- or noise- induced hearing loss. In one aspect, use of Niclosamide, Ingenol, and Elesclomol as an active agent to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
-
公开(公告)号：WO2022010167A1
公开(公告)日：2022-01-13
申请号：PCT/KR2021/008278
申请日：2021-06-30
申请人： 연세대학교 산학협력단
IPC分类号： C12N15/52 , C12N9/18 , C12N15/70 , A61K38/46 , A61K31/22 , A61K39/108 , C12N15/74 , A61P1/00 , C12R1/19
摘要： 본 명세서에서는, 서열번호 1의 염기서열과 80 % 이상의 상동성을 갖고, 에스터레이즈 (esterase) 를 코딩하는, 폴리뉴클레오타이드 및 이의 용도가 제공된다.
-
-
-
-
-
-
-
-
-
搜索结果
1390 条记录 (耗时 0.027 秒)
